局部进展期胰腺癌综合治疗的研究进展

doi:10.16139/j.1007-9610.2020.05.019

摘要/Abstract

中图分类号:

R735.9

钱梨寒, 沈柏用. 局部进展期胰腺癌综合治疗的研究进展[J]. 外科理论与实践, 2020, 25(05): 442-446.

QIAN Lihan, SHN Baiyong. Research progress on comprehensive treatment of locally advanced pancreatic cancer[J]. Journal of Surgery Concepts & Practice, 2020, 25(05): 442-446.

参考文献 32

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34.
[2]	Tempero MA, Malafa MP, Chiorean EG, et al. Pancreatic Adenocarcinoma, Version 1.2019[J]. J Natl Compr Canc Netw, 2019, 17(3):202-210.
[3]	Fogelman D, Sugar EA, Oliver G, et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma[J]. Cancer Chemother Pharmacol, 2015, 76(3):489-498.
[4]	Rahma OE, Duffy A, Liewehr DJ, et al. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials[J]. Ann Oncol, 2013, 24(8):1972-1979. doi: 10.1093/annonc/mdt166 pmid: 23670093
[5]	Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial[J]. J Clin Oncol, 1997, 15(6):2403-2413. doi: 10.1200/JCO.1997.15.6.2403 pmid: 9196156
[6]	von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gem-citabine[J]. New Engl J Med, 2013, 369(18):1691-1703.
[7]	Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364(19):1817-1825.
[8]	Marthey L, Sa-Cunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort[J]. Ann Surg Oncol, 2015, 22(1):295-301. doi: 10.1245/s10434-014-3898-9 pmid: 25037971
[9]	Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis[J]. Lancet Oncol, 2016, 17(6):801-810.
[10]	Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial[J]. Lancet Oncol, 2013, 14(4):317-326. doi: 10.1016/S1470-2045(13)70021-4 pmid: 23474363
[11]	Akahori T, Sho M, Yanagimoto H, et al. Phase Ⅱ study of the triple combination chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma[J]. Oncologist, 2019, 24(6):749-e224.
[12]	Sultana A, Tudur Smith C, Cunningham D, et al. Syste-matic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy[J]. Br J Cancer, 2007, 96(8):1183-1190.
[13]	Hammel P, Huguet F, van Laethem J, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib[J]. JAMA, 2016, 315(17):1844-1853.
[14]	Faris JE, Blaszkowsky LS, Mcdermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience[J]. Oncologist, 2013, 18(5):543-548.
[15]	Cattaneo GM, Passoni P, Longobardi B, et al. Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma[J]. Radiother Oncol, 2013, 108(1):66-71.
[16]	Prasad S, Cambridge L, Huguet F, et al. Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer[J]. Pract Radiat Oncol, 2016, 6(2):78-85.
[17]	Fowler JF, Welsh JS, Howard SP. Loss of biological effect in prolonged fraction delivery[J]. Int J Radiat Oncol Biol Phys, 2004, 59(1):242-249.
[18]	Song Y, Yuan Z, Li F, et al. Analysis of clinical efficacy of CyberKnife^® treatment for locally advanced pancreatic cancer[J]. Onco Targets Ther, 2015, 8:1427-1431.
[19]	Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer[J]. Nature, 2016, 531(7592):47-52.
[20]	Lee J, Jang KT, Ki CS, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma[J]. Cancer, 2007, 109(8):1561-1569.
[21]	Schultheis B, Reuter D, Ebert MP, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase Ⅱb study[J]. Ann Oncol, 2017, 28(10):2429-2435. doi: S0923-7534(19)34947-6 pmid: 28961832
[22]	Waddell N, Pajic M, Patch A, et al. Whole genomes redefine the mutational landscape of pancreatic cancer[J]. Nature, 2015, 518(7540):495-501.
[23]	Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancrea-tic cancer: outcomes from the CONKO-003 trial[J]. J Clin Oncol, 2014, 32(23):2423-2429.
[24]	Watkins JA, Irshad S, Grigoriadis A, et al. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers[J]. Breast Cancer Res, 2014, 16(3):211.
[25]	Shroff RT, Hendifar A, Mcwilliams RR, et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation[J]. JCO Precis Oncol, 2018, 2018:10.1200/PO.17.00316. doi: 10.1200/PO.17.00316. doi: 10.1200/PO.17.00316 URL
[26]	Hammel P, Kindler HL, Reni M, et al. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib[J]. Ann Oncol, 2019, 30(12):1959-1968. doi: S0923-7534(20)32559-X pmid: 31987299
[27]	Sahin IH, Askan G, Hu ZI, et al. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?[J]. Ann Oncol, 2017, 28(12):2950-2961. doi: 10.1093/annonc/mdx503 pmid: 28945842
[28]	Sahin IH, Lowery MA, Stadler ZK, et al. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches[J]. Expert Rev Gastroenterol Hepatol, 2016, 10(8):893-905.
[29]	Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin(CRS-207) boost vaccines for metastatic pancreatic cancer[J]. J Clin Oncol, 2015, 33(12):1325-1333. doi: 10.1200/JCO.2014.57.4244
[30]	Chung MJ, Park JY, Bang S, et al. Phase Ⅱ clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer[J]. Cancer Immunol Im-munother, 2014, 63(9):939-946.
[31]	Balaban EP, Mangu PB, Yee NS. Locally advanced unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary[J]. J Oncol Pract, 2017, 13(4):265-269. doi: 10.1200/JOP.2016.017376 pmid: 28399382
[32]	栗志磊, 范新奇, 包伟, 等. 局部进展期胰腺癌的诊治策略进展[J]. 中华肝胆外科杂志, 2018, 24(11):789-792.

局部进展期胰腺癌综合治疗的研究进展

Research progress on comprehensive treatment of locally advanced pancreatic cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 32

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙祺, 黄文博, 何炳良, 刘畅, 徐宇航, 赵伟. 预防性腹腔热灌注化疗对局部进展期胃癌根治术后病人预后改善的有效性研究[J]. 外科理论与实践, 2023, 28(04): 366-370.
[2]	韩序, 王文权, 楼文晖, 刘亮. 免疫检查点抑制剂治疗胃肠胰神经内分泌肿瘤的进展[J]. 外科理论与实践, 2023, 28(03): 267-272.
[3]	朱颖, 汤玉茗, 黄佳, 章永平, 姚玮艳. 全反式维A酸可促进肿瘤相关诱导配体对多种胰腺癌细胞的凋亡作用[J]. 内科理论与实践, 2023, 18(03): 171-176.
[4]	杨盈赤, 庞凯, 张忠涛. 新辅助放疗联合免疫治疗对直肠癌微创术式应用的影响[J]. 外科理论与实践, 2023, 28(03): 186-189.
[5]	王远江, 邹浩. 胆囊癌综合治疗的临床研究[J]. 外科理论与实践, 2023, 28(02): 171-176.
[6]	邢颖, 程石. 胆囊癌新辅助治疗的现状和争议[J]. 外科理论与实践, 2023, 28(02): 110-114.
[7]	李建芳, 余俊贤, 严超, 朱正纲, 刘炳亚. 胃癌基础与转化研究的热点问题[J]. 外科理论与实践, 2023, 28(01): 7-16.
[8]	张天羽, 周东, 洪桢. 《儿童抗NMDAR脑炎治疗的国际共识推荐》解读[J]. 诊断学理论与实践, 2022, 21(06): 677-683.
[9]	任佳逸, 糜坚青. 新型抗体类药物在急性B淋巴细胞白血病中的治疗进展[J]. 内科理论与实践, 2022, 17(06): 463-467.
[10]	杨蕊馨, 杜宇童, 燕然林, 朱正纲, 李琛, 于颖彦. 消化道肿瘤单细胞转录组测序研究中生物样本前处理改良的探索[J]. 诊断学理论与实践, 2022, 21(05): 567-574.
[11]	王杰强综述, 马德奎审校. Trop2基因与三阴性乳腺癌的研究进展[J]. 外科理论与实践, 2022, 27(05): 473-477.
[12]	李佳, 吕良敬. 靶向治疗时代议自身免疫病的感染挑战[J]. 诊断学理论与实践, 2022, 21(03): 299-303.
[13]	许梓枫综述, 宗雅萍, 陆爱国审校. 局部进展期结肠癌病人的新辅助治疗[J]. 外科理论与实践, 2022, 27(03): 266-270.
[14]	张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜. 肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157.
[15]	于颖彦. 免疫检查点及其抑制剂的发展[J]. 内科理论与实践, 2022, 17(01): 48-52.